MyMedR

Fulltext ASGO's Fourth Biennial Meeting, November 12th to 14th, 2015

Kumarasamy S

J Gynecol Oncol, 2016 Jan;27(1):e10.

PMID: 26676383 DOI: 10.3802/jgo.2016.27.e10

Fulltext Asian Society of Gynecologic Oncology International Workshop 2014

Park JY, Ngan HY, Park W, Cao Z, Wu X, Ju W, et al.

J Gynecol Oncol, 2015 Jan;26(1):68-74.

PMID: 25609163 DOI: 10.3802/jgo.2015.26.1.68

The Asian Society of Gynecologic Oncology International Workshop 2014 on gynecologic oncology was held in Asan Medical Center, Seoul, Korea on the 23rd to 24th August 2014. A total of 179 participants from 17 countries participated in the workshop, and the up-to-date findings on the management of gynecologic cancers were presented and discussed. This meeting focused on the new trends in the management of cervical cancer, fertility-sparing management of gynecologic cancers, surgical management of gynecologic cancers, and recent advances in translational research on gynecologic cancers.

Fulltext Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings

Wilailak S, Chan KK, Chen CA, Nam JH, Ochiai K, Aw TC, et al.

J Gynecol Oncol, 2015 Jan;26(1):46-53.

PMID: 25310857 DOI: 10.3802/jgo.2015.26.1.46

The purpose of this study was to develop a risk prediction score for distinguishing benign ovarian mass from malignant tumors using CA-125, human epididymis protein 4 (HE4), ultrasound findings, and menopausal status. The risk prediction score was compared to the risk of malignancy index and risk of ovarian malignancy algorithm (ROMA).

Fulltext Asian Society of Gynecologic Oncology International Workshop 2018

Kong TW, Ryu HS, Kim SC, Enomoto T, Li J, Kim KH, et al.

J Gynecol Oncol, 2019 Mar;30(2):e39.

PMID: 30740961 DOI: 10.3802/jgo.2019.30.e39

The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discuss the latest findings of gynecologic cancer, including cervical, ovarian, and endometrial cancers, as well as the future of fertility-sparing treatments, minimally invasive/radical/debulking surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Clinical guidelines and position statement of Asian countries were presented by experts. Asian clinical trials for gynecologic cancers were reviewed and experts emphasized the point that original Asian study is beneficial for Asian patients. In Junior session, young gynecologic oncologists presented their latest research on gynecologic cancers.

Fulltext Asian Young Doctors Session at the 64th Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO): Educational Initiatives in the Next Generation for a New Era after the COVID-19 Pandemic

Kobayashi Y, Komatsu H, Isobe M, Meena J, Weng CS, Kim SI, et al.

J Gynecol Oncol, 2023 Jan;34(1):e22.

PMID: 36509465 DOI: 10.3802/jgo.2023.34.e22

Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)

Yun BS, Lee KB, Lee KH, Chang HK, Kim JY, Lim MC, et al.

J Gynecol Oncol, 2024 Jan 22.

PMID: 38330380 DOI: 10.3802/jgo.2024.35.e57

BACKGROUND: Bulky or multiple lymph node (LN) metastases are associated with poor prognosis in cervical cancer, and the size or number of LN metastases is not yet reflected in the staging system and therapeutic strategy. Although the therapeutic effects of surgical resection of bulky LNs before standard treatment have been reported in several retrospective studies, well-planned randomized clinical studies are lacking. Therefore, the aim of the Korean Gynecologic Oncology Group (KGOG) 1047/DEBULK trial is to investigate whether the debulking surgery of bulky or multiple LNs prior to concurrent chemoradiation therapy (CCRT) improves the survival rate of patients with cervical cancer IIICr diagnosed by imaging tests.

METHODS: The KGOG 1047/DEBULK trial is a phase III, multicenter, randomized clinical trial involving patients with bulky or multiple LN metastases in cervical cancer IIICr. This study will include patients with a short-axis diameter of a pelvic or para-aortic LN ≥2 cm or ≥3 LNs with a short-axis diameter ≥1 cm and for whom CCRT is planned. The treatment arms will be randomly allocated in a 1:1 ratio to either receive CCRT (control arm) or undergo surgical debulking of bulky or multiple LNs before CCRT (experimental arm). CCRT consists of extended-field external beam radiotherapy/pelvic radiotherapy, brachytherapy and LN boost, and weekly chemotherapy with cisplatin (40 mg/m²), 4-6 times administered intravenously. The primary endpoint will be 3-year progression-free survival rate. The secondary endpoints will be 3-year overall survival rate, treatment-related complications, and accuracy of radiological diagnosis of bulky or multiple LNs.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05421650; Clinical Research Information Service Identifier: KCT0007137.

Displaying all 6 publications